Translational Pain Research Program Department of Neurosurgery, University of Rochester School of Medicine and Dentistry, Rochester, New York.
OrthoCarolina Spine Center, Charlotte, North Carolina.
Neurosurgery. 2020 Mar 1;86(3):343-347. doi: 10.1093/neuros/nyz093.
Chronic low back pain (CLBP) is a primary indication for opioid therapy.
To evaluate the hypothesis that CLBP patients reporting reduced opioid use have superior functional outcomes following basivertebral nerve (BVN) radiofrequency ablation.
This post hoc analysis from a sham-controlled trial examined short-acting opioid use from baseline through 1 yr. Opioid use was stratified into 3 groups by two blinded external reviewers. Two-sample t-tests were used to compare Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) measurements between those patients who increased or decreased their opioid usage compared to baseline.
Actively treated patients with decreased opioid use at 12 mo had a mean ODI improvement of 24.9 ± 16.0 (n = 27) compared to 7.3 ± 9.8 (n = 18) for patients reporting increased opioid use (P < .001). In the sham arm, the improvements in ODI were 17.4 ± 16.1 (n = 19) and 1.2 ± 14.3 (n = 5; P = .053) for the patients reporting decreased vs increased opioid usage, respectively. Actively treated patients reporting decreased opioid use had a mean improvement in VAS of 3.3 ± 2.5 (n = 27) compared to 0.6 ± 1.8 (n = 18) for patients reporting increased opioid use (P < .001). In the sham arm, the improvements in VAS were 2.5 ± 2.6 (n = 19) and 1.4 ± 1.9 (n = 5; P = .374) for patients reporting decreased vs increased opioid use, respectively.
Subjects undergoing BVN ablation who decreased opioid use had greater improvement in ODI and VAS scores compared with those reporting increased opioid usage. There is an association between functional benefit from BVN ablation and reduced opioid use.
慢性下腰痛(CLBP)是阿片类药物治疗的主要指征。
评估以下假设,即报告减少阿片类药物使用的 CLBP 患者在接受基底神经节射频消融(BVN)后具有更好的功能结果。
本研究为假对照试验的事后分析,通过 2 位盲法外部评审员,检查短期阿片类药物使用情况,从基线到 1 年。将阿片类药物使用情况分为 3 组。使用两样本 t 检验比较与基线相比增加或减少阿片类药物使用的患者之间的 Oswestry 残疾指数(ODI)和视觉模拟量表(VAS)测量值。
在 12 个月时减少阿片类药物使用的活跃治疗患者的 ODI 平均改善为 24.9±16.0(n=27),而报告增加阿片类药物使用的患者为 7.3±9.8(n=18;P<0.001)。在假手术组中,报告减少与增加阿片类药物使用的患者的 ODI 改善分别为 17.4±16.1(n=19)和 1.2±14.3(n=5;P=0.053)。报告减少阿片类药物使用的活跃治疗患者的 VAS 平均改善为 3.3±2.5(n=27),而报告增加阿片类药物使用的患者为 0.6±1.8(n=18;P<0.001)。在假手术组中,报告减少与增加阿片类药物使用的患者的 VAS 改善分别为 2.5±2.6(n=19)和 1.4±1.9(n=5;P=0.374)。
接受 BVN 消融的阿片类药物使用减少的患者在 ODI 和 VAS 评分方面的改善大于报告阿片类药物使用增加的患者。从 BVN 消融中获得的功能益处与减少阿片类药物使用之间存在关联。